1) Demirbaş A, Elmas ÖF, Türsen Ü, Atasoy M, Lotti T. Superficial thrombophlebitis in a patient with COVID 19: Heparin treatment after evaluation of D-Dimer. Dermatol Ther. 2020; 33(4): e13768.
2) Marone EM, Bonalumi G, Curci R, et al. Characteristics of Venous Thromboembolism in COVID-19 Patients: A Multicenter Experience from Northern Italy. Ann Vasc Surg. 2020; 68: 83-87.
3) Feng Y, Ling Y, Bai T, et al. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Am J Respir Crit Care Med. 2020; 201(11): 1380-1388.
4) Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061-1069.
5) Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020; 18(8): 1995-2002.
6) Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020; 46(6): 1089-1098.
7) Suh YJ, Hong H, Ohana M, et al. Pulmonary Embolism and Deep Vein Thrombosis in COVID-19: A Systematic Review and Meta-Analysis. Radiology. 2021; 298(2): E70-E80.
8) Hadid T, Kafri Z, Al-Katib A. Coagulation and anticoagulation in COVID-19. Blood Rev. 2021; 47: 100761.
9) Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020; 383(2): 120-128.
10) Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020; 126(10): 1456-1474.
11) Decousus H, Leizorovicz A. Superficial thrombophlebitis of the legs: still a lot to learn. J Thromb Haemost. 2005; 3(6): 1149-1151.
12) Dargon PT, Landry GJ. Buerger's disease. Ann Vasc Surg. 2012; 26(6): 871-880.
13) Evans NS, Ratchford EV. Catheter-related venous thrombosis. Vasc Med. 2018; 23(4): 411-413.
14) Read II, Luna M, Khalil SA, Costerton JW, Lam C, Bodey GP. The relationship between the thrombotic and infectious complications of central venous catheters. JAMA. 1994; 271(13): 1014-1016.
15) Hernandez D, Diaz F, Suria S, et al. Subclavian catheter-related infection is a major risk factor for the late development of subclavian vein stenosis. Nephrol Dial Transplant. 1993; 8(3): 227-230.
16) Crnich CJ, Maki DG. The promise of novel technology for the prevention of intravascular device–related bloodstream infection. II. Long-term devices. Clin Infect Dis. 2002; 34(10): 1362-1368.
17) Ashton J, Gibson V, Summers S. Effects of heparin versus saline solution on intermittent infusion device irrigation. Heart Lung. 1990; 19(6): 608-612.
18) Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet. 1973; 136(3): 409-416.
19) O’Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Infect Control Hosp Epidemiol. 2002; 23(12): 759-769.
20) Tager IB, Ginsberg MB, Ellis SE, et al. An epidemiologic study of the risks associated with peripheral intravenous catheters. Am J Epidemiol. 1983; 118(6): 839-851.